* Deciphera Pharmaceuticals Inc DCPH.OQ DCPH.O is
expected
to show a rise in quarterly revenue when it reports results on
May 3.
* The Waltham Massachusetts-based company is expected to
report
a 22.5% increase in revenue to $35.796 million from $29.22
million a year ago, according to the mean estimate from 11
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Deciphera
Pharmaceuticals
Inc is for a loss of 59 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Deciphera
Pharmaceuticals Inc is $22, above its last closing price
of $14.21.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.55 -0.56 -0.60 Missed -7.6
Sep. 30 2022 -0.57 -0.58 -0.55 Beat 4.6
Jun. 30 2022 -0.65 -0.66 -0.60 Beat 8.8
Mar. 31 2022 -0.94 -0.90 -0.80 Beat 11.2
Dec. -1.49 -1.38 -1.51 Missed -9.5
31 2021
Sep. 30 2021 -1.27 -1.28 -1.37 Missed -7.4
Jun. 30 2021 -1.16 -1.15 -1.21 Missed -4.8
Mar. 31 2021 -1.07 -1.06 -1.06 Met 0.3
This summary was machine generated May 1 at 18:13 GMT. All
figures in US dollars unless otherwise stated